Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up

[21] Drucker DJ(2013)Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes Circ J 77 1337-135

[22] Green JB(2014)DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study Cardiovasc Diabetol 13 110-528

[23] Bethel MA(2013)Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients J Am Heart Assoc 2 e003277-2298

[24] Armstrong PW(2014)A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study Cardiovasc Diabetol 13 96-150

[25] Buse JB(2015)Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus Diabetes Metab Syndr Obes 27 339-339

[26] Engel SS(2013)The cardiovascular safety of incretin-based therapies: a review of the evidence Cardiovasc Diabetol 12 130-439

[27] Garg J(2008)Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension J Clin Pharmacol 48 592-249

[28] Josse R(2011)Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes Tohoku J Exp Med 223 133-1200

[29] Kaufman KD(2011)Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats J Hypertens 29 520-339

[30] Koglin J(2013)Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials Cardiovasc Diabetol 12 60-46

[21] Drucker DJ(2013)Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes Circ J 77 1337-135

[22] Green JB(2014)DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study Cardiovasc Diabetol 13 110-528

[23] Bethel MA(2013)Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients J Am Heart Assoc 2 e003277-2298

[24] Armstrong PW(2014)A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study Cardiovasc Diabetol 13 96-150

[25] Buse JB(2015)Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus Diabetes Metab Syndr Obes 27 339-339

[26] Engel SS(2013)The cardiovascular safety of incretin-based therapies: a review of the evidence Cardiovasc Diabetol 12 130-439

[27] Garg J(2008)Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension J Clin Pharmacol 48 592-249

[28] Josse R(2011)Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes Tohoku J Exp Med 223 133-1200

[29] Kaufman KD(2011)Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats J Hypertens 29 520-339

[30] Koglin J(2013)Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials Cardiovasc Diabetol 12 60-46